Zobrazeno 1 - 10
of 293
pro vyhledávání: '"A I Kochetkov"'
Publikováno v:
Терапевтический архив, Vol 92, Iss 1, Pp 69-75 (2020)
Insomnia is frequently detected in patients with arterial hypertension (AH): from 19% to 47.9% of all cases according to epidemiological studies. On the other hand, the frequency of hypertension in patients with insomnia ranges from 21.4% to 50.2%, w
Externí odkaz:
https://doaj.org/article/36152a6fac1747c0b7dc37d5d520269b
Autor:
O D Ostroumova, A I Kochetkov, A P Pereverzev, E V Kravchenko, A N Kazjulin, D N Andreev, E E Pavleeva
Publikováno v:
Терапевтический архив, Vol 91, Iss 8, Pp 118-126 (2019)
In the article the problem of the combined use of clopidogrel and various proton pump inhibitors (PPIs) in terms of cardiovascular complications risk and stent thrombosis is considered. The results of meta - analyses and a systematic reviews affectin
Externí odkaz:
https://doaj.org/article/f613e1f9948e49cab7f148a114c0ed49
Autor:
O D Ostroumova, A I Kochetkov
Publikováno v:
Системные гипертензии, Vol 15, Iss 4, Pp 8-16 (2018)
The review from the standpoint of the newest European guidelines for the diagnosis and treatment of arterial hypertension discusses the role of highly selective b-blockers and, above all, the superior member of these drugs - bisoprolol in blood press
Externí odkaz:
https://doaj.org/article/681c23413b87494a95c6badea75e8e37
Autor:
O D Ostroumova, A I Kochetkov
Publikováno v:
Терапевтический архив, Vol 90, Iss 9, Pp 123-132 (2018)
The review presents a modern view on stress as a risk factor for the development of arterial hypertension (AH). A variety pathogenic mechanisms responsible for increase of blood pressure during stress exposure are described in detail. The importance
Externí odkaz:
https://doaj.org/article/c4c31777ca8c42e8944999510b4a65e6
Autor:
O D Ostroumova, A I Kochetkov
Publikováno v:
Системные гипертензии, Vol 15, Iss 1, Pp 23-31 (2018)
Objective. To conduct a comparative analysis of blood pressure (BP) profile characteristics in middle-aged (45-65 years) patients with stage 1-2 hypertension not associated with comorbid cardiovascular disease depending on smoking status; to estimate
Externí odkaz:
https://doaj.org/article/d4740d1415394d8688559d3f7202b824
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 17-23 (2016)
The article discusses the factors that increase the arterial stiffness: the blood pressure, atherosclerosis, smoking, diabetes, age. Given evidence that pulse wave velocity and a number of other indicators that reflect the state of the vascular wall,
Externí odkaz:
https://doaj.org/article/2840035019244f3cacf2a762c02ce9b2
Publikováno v:
Системные гипертензии, Vol 12, Iss 2, Pp 43-48 (2015)
The article deals with the role of the hardness of the vessel wall in the pathogenesis of arterial hypertension and its complications and cardiovascular mortality. We discussed the factors increasing the hardness of the vessel wall, such as age, bloo
Externí odkaz:
https://doaj.org/article/585f377b05f54ffeb9ff2d2618c3fcf5
Autor:
N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 19, Iss 5, Pp 470-478 (2023)
Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in p
Externí odkaz:
https://doaj.org/article/9a8bd307ca844343b2cc8835a800342f
Autor:
D. A. Sychev, T. M. Ostroumova, O. D. Ostroumova, A. I. Kochetkov, S. V. Batyukina, E. V. Mironova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 3, Pp 252-270 (2023)
Scientific relevance. Being the main class of medicinal products for dyslipidaemia treatment, statins are widely used in clinical practice in various patient populations. However, statins can cause statin-associated muscle symptoms (SAMS), which are
Externí odkaz:
https://doaj.org/article/cccf47b56b034a00b308084e90c41533
Publikováno v:
Consilium Medicum, Vol 25, Iss 5, Pp 368-374 (2023)
Prevention of thromboembolic complications is the main goal in patients with atrial fibrillation. Anticoagulant therapy is used as prophylaxis, and direct oral anticoagulants are preferred. However, this therapy is associated with a risk of bleeding,
Externí odkaz:
https://doaj.org/article/3e4a99d168c74f388385a9787ec43287